- Home
- VGI vs ASRT Comparison
VGI vs ASRT Comparison
Compare VGI & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGI
- ASRT
- Stock Information
- Founded
- VGI 2012
- ASRT 1995
- Country
- VGI United States
- ASRT United States
- Employees
- VGI N/A
- ASRT N/A
- Industry
- VGI Investment Managers
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- VGI Finance
- ASRT Health Care
- Exchange
- VGI Nasdaq
- ASRT Nasdaq
- Market Cap
- VGI 90.1M
- ASRT 83.2M
- IPO Year
- VGI N/A
- ASRT 1997
- Fundamental
- Price
- VGI $7.79
- ASRT $0.74
- Analyst Decision
- VGI
- ASRT Strong Buy
- Analyst Count
- VGI 0
- ASRT 1
- Target Price
- VGI N/A
- ASRT $3.00
- AVG Volume (30 Days)
- VGI 46.0K
- ASRT 614.0K
- Earning Date
- VGI 01-01-0001
- ASRT 11-10-2025
- Dividend Yield
- VGI 12.66%
- ASRT N/A
- EPS Growth
- VGI N/A
- ASRT N/A
- EPS
- VGI N/A
- ASRT N/A
- Revenue
- VGI N/A
- ASRT $137,354,000.00
- Revenue This Year
- VGI N/A
- ASRT N/A
- Revenue Next Year
- VGI N/A
- ASRT $4.10
- P/E Ratio
- VGI N/A
- ASRT N/A
- Revenue Growth
- VGI N/A
- ASRT N/A
- 52 Week Low
- VGI $6.68
- ASRT $0.51
- 52 Week High
- VGI $7.99
- ASRT $1.08
- Technical
- Relative Strength Index (RSI)
- VGI 39.81
- ASRT 42.18
- Support Level
- VGI $7.80
- ASRT $0.71
- Resistance Level
- VGI $7.95
- ASRT $0.95
- Average True Range (ATR)
- VGI 0.09
- ASRT 0.06
- MACD
- VGI -0.01
- ASRT 0.00
- Stochastic Oscillator
- VGI 41.03
- ASRT 17.36
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.